Clinical Trials

Inclusion Criteria:

1. Participation in IRB protocol #16-007897
2. Adults, age 18 and older
3. Untreated male patients with moderate- to high-risk prostate cancer, who have had a clinical pelvic mpMRI as standard clinical care for diagnosis and management of prostate cancer.
4. Pathologically confirmed Gleason ≥ 7 prostate cancers that are scheduled for surgical prostatectomy.

Exclusion Criteria:

1. Patients who already received primary treatment or neo-adjuvant therapy.
2. Patients who refuse undergoing routine clinical imaging (i.e., pelvic mpMRI) for staging.
3. Patients who cannot tolerate MRI (e.g., claustrophobia, severe back pain or spasm, involuntary movement [e.g., tremor, dystonia]).
4. Patients who have total hip arthroplasty (THA), which can cause substantial susceptibility artifact and degrade image quality of mpMRI.
5. Patients have cardiac pacemaker, cochlear implants, neurostimulator, medical device which is unsafe at 3 Tesla, or foreign metallic body in the eyes or orbit.
6. Patients have contraindication to gadolinium based MR contrast agents (e.g., renal failure, severe reaction to gadolinium based MR contrast agents). eGFR should be above 30 within 30 days the time of mpMRI.